Can-Fite BioPharma’s (CANF) Buy Rating Reaffirmed at HC Wainwright

Posted by Matthew Steigler on Nov 15th, 2024

HC Wainwright reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $18.00 target price on the stock. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

Several other analysts also recently weighed in on the stock. StockNews.com downgraded shares of Can-Fite BioPharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

View Our Latest Research Report on Can-Fite BioPharma

Can-Fite BioPharma Stock Up 3.0 %

Shares of NYSE CANF traded up $0.06 during midday trading on Tuesday, reaching $2.05. 3,404 shares of the stock were exchanged, compared to its average volume of 67,411. Can-Fite BioPharma has a twelve month low of $1.83 and a twelve month high of $4.69. The company has a 50 day simple moving average of $2.26 and a 200 day simple moving average of $2.52.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its position in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.